Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;12(1):203.
doi: 10.1186/ar2903. Epub 2010 Feb 15.

The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis

Ger Jm Pruijn  1 , Allan Wiik, Walther J van Venrooij
Affiliations
Review

The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis

Ger Jm Pruijn et al. Arthritis Res Ther. 2010.

Abstract

The presence or absence of antibodies to citrullinated peptides/proteins (ACPA) is an important parameter that helps a clinician set a diagnosis of early rheumatoid arthritis and, hence, initiate treatment. There are several commercial tests available to measure ACPA levels, although it can be difficult to decide what the best test for a given clinical question is. We analyzed literature data in which the diagnostic and other properties of various ACPA tests are compared. The results show that for diagnostic purposes the CCP2 test has the highest specificity, the highest sensitivity in stratified studies and the highest positive predictive value. For the prediction of future joint destruction the CCP2, MCV, and CCP3 tests may be used. The ability to predict the likelihood of not achieving sustained disease-modifying antirheumatic drug-free remission was highest for the CCP2 test. Finally, the levels of anti-CCP2 and anti-CCP3 (and possibly anti-mutated citrullinated vimentin) in rheumatoid arthritis patients are not significantly influenced by TNFalpha blocking agents.

PubMed Disclaimer

References

    1. Van Venrooij WJ, Van Beers JJBC, Pruijn GJM. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann NY Acad Sci. 2008;1143:268–285. doi: 10.1196/annals.1443.013. - DOI - PubMed
    1. Helm-van Mil AH Van der, Verpoort KN, Breedveld FC, Toes REM, Huizinga TWJ. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–R958. doi: 10.1186/ar1767. - DOI - PMC - PubMed
    1. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, Frisch M. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther. 2006;8:R133. doi: 10.1186/ar2022. - DOI - PMC - PubMed
    1. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz dR, Sanchez-Ramon S, Rodriguez-Mahou M, Paravisini A, Monteagudo I, Gonzalez CM, Garcia-Castro M, Casas MD, Carreno L. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419–424. doi: 10.1002/art.24390. - DOI - PubMed
    1. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, Speyer I, Westedt ML, Peeters AJ, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424–1432. doi: 10.1002/art.22525. - DOI - PubMed